212 related articles for article (PubMed ID: 605911)
1. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Case DC; Lee DJ; Clarkson BD
Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
[No Abstract] [Full Text] [Related]
2. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
[No Abstract] [Full Text] [Related]
3. Combination therapy for multiple myeloma.
Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
[TBL] [Abstract][Full Text] [Related]
4. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
Presant CA; Klahr C
Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
[TBL] [Abstract][Full Text] [Related]
7. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
8. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
[No Abstract] [Full Text] [Related]
9. [Chemotherapy of multiple myeloma. Review of the recent trials].
Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
[No Abstract] [Full Text] [Related]
10. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
Case DC
Blood; 1982 May; 59(5):934-7. PubMed ID: 6803856
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma: a randomized study of three different regimens.
Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
13. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
[No Abstract] [Full Text] [Related]
14. [Treatment of Kahler's disease].
Foa J; Carcassonne Y
Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
[No Abstract] [Full Text] [Related]
15. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
Kyle RA; Jacobus S; Friedenberg WR; Slabber CF; Rajkumar SV; Greipp PR
Cancer; 2009 May; 115(10):2155-64. PubMed ID: 19248045
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of myelomatosis on treatment with prednisone and cytostatics.
Hansen OP; Jessen B; Videbaek A
Scand J Haematol; 1973; 10(4):282-90. PubMed ID: 4764610
[No Abstract] [Full Text] [Related]
17. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
Cavo M; Galieni P; Tassi C; Gobbi M; Tura S
Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in chemotherapy of multiple myeloma].
Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G
Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935
[No Abstract] [Full Text] [Related]
19. An overview of the status of the nitrosoureas in other tumors.
Carter SK
Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
[No Abstract] [Full Text] [Related]
20. Plasma cell myeloma. An interpretive review.
Bergsagel DE
Cancer; 1972 Dec; 30(6):1588-94. PubMed ID: 4565818
[No Abstract] [Full Text] [Related]
[Next] [New Search]
